Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Profound Medical Corp (TSX: PRN )

9.910 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Mar 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 9.910
Bid (Size) 9.250 (20)
Ask (Size) 10.80 (14)
Prev. Close 9.910
Today's Range 9.910 - 9.910
52wk Range 7.900 - 15.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire

Performance

YTD
-13.30%
-13.30%
1 Month
+15.91%
+15.91%
3 Month
-8.75%
-8.75%
6 Month
-9.08%
-9.08%
1 Year
-8.24%
-8.24%

More News

Read More
Update: Profound Medical’s Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Proposed Public Offering of Common Shares
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in the Stifel 2024 Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Third Quarter 2024 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Second Quarter 2024 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Annual General Meeting of Shareholders Voting Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
From Profound Medical Corp.
Via GlobeNewswire
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.